Medicine
Zerviate 2.4 mg/mL powder for ophthalmic solution
Zerviate 2.4 mg/mL powder for ophthalmic solution is a prescription medicine containing Cetirizine for ophthalmic use, marketed by Harrow Eye, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 25°C (59°F to 77°F). Single-use containers should be stored…
Key facts
- Active ingredient (INN)
- Cetirizine
- Brand
- Zerviate
- Strength
- 2.4 mg/mL
- Dosage form
- Powder for ophthalmic solution
- Route
- Ophthalmic
- Packs
- 1 pouch
- Marketing authorisation holder
- Harrow Eye
- Manufacturer
- Harrow Eye
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 25°C (59°F to 77°F). Single-use containers should be stored in the original foil pouch.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R06AE07 Cetirizine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 April 2025
- Identifiers
- RxCUI 2119476, 2119481DailyMed set ID 6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59NDC 82667-015Application NDA208694
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 30 vial, single-use in 1 pouch / 2.5 mL in 1 vial, single-use | 82667-015-24 | Harrow Eye | 31 December 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 December 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cetirizine
Clinical summary
Cetirizine is a histamine-1 receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis. It is available as oral solution, injection and powder for ophthalmic solution for intravenous use. MedsAcross supplies Cetirizine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CetirizineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZERVIATE prescribing information (Harrow Eye) · U.S. National Library of Medicine, DailyMed
Need Zerviate 2.4 mg/mL powder for ophthalmic solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.